论文部分内容阅读
目的:评价自体造血干细胞移植治疗T细胞非霍奇金淋巴瘤的临床疗效及安全性。方法:回顾性分析T细胞非霍奇金淋巴瘤28例患者的资料,其中单次移植5例,双次移植23例。第1次移植预处理方案分别为:IEP方案19例,MiFAP方案9例。第2次移植预处理方案分别为:IEP方案9例,MiFAP方案14例。2次移植间隔为8(6～10)周。结果:所有患者均获得造血功能重建。无一例移植相关死亡。随访至2011年2月1日,中位随访时间28(2～98)个月。复发8例,经治疗无效均于复发后1～6个月死亡。5例单次移植患者复发3例(60%),23例双次移植患者复发5例(21.7%)。23例双次移植患者1年、3年预期生存率分别为95.7%和76.1%,1年、3年预期无进展生存率分别为95.7%和71.5%。23例双次移植患者预期中位无进展生存时间60个月,5例单次移植患者预期中位无进展生存时间18个月。结论:双次移植对预后不良、化疗效果欠佳的T细胞非霍奇金淋巴瘤疗效良好,安全性好。
Objective: To evaluate the clinical efficacy and safety of autologous hematopoietic stem cell transplantation in the treatment of T cell non-Hodgkin’s lymphoma. Methods: The data of 28 patients with T-cell non-Hodgkin’s lymphoma were retrospectively analyzed. Among them, 5 were single and 23 were double-transplant. The first transplant pretreatment programs were: IEP program in 19 cases, MiFAP program in 9 cases. The second transplant pretreatment programs were: IEP program in 9 cases, MiFAP program in 14 cases. 2 transplant interval of 8 (6 ~ 10) weeks. Results: All patients received hematopoietic reconstitution. None of the transplant-related deaths. Follow-up to February 1, 2011, the median follow-up time 28 (2 to 98) months. Recurrent in 8 cases, after treatment were ineffective in 1 to 6 months after the death of death. Three of five patients (60%) had a single recurrence, and five patients (21.7%) had a second relapse in 23 patients. The prospective survival rates were 95.7% and 76.1% for 1 year and 3 years respectively in 23 patients with double-transplantation. The expected progression-free survival rates at 1 year and 3 years were 95.7% and 71.5% respectively. The median progression-free survival time was expected to be 60 months in 23 patients with double-grafting and 5 months in 5 patients with a median expected progression-free survival of 18 months. CONCLUSION: Double-grafting has good efficacy and safety for T-cell non-Hodgkin’s lymphoma with poor prognosis and poor response to chemotherapy.